Abstract

ObjectiveTo establish an easy and practical assay for identifying systemic interferon (IFN) type I bioactivity in patients with primary Sjögren's syndrome (pSS). The IFN type I signature is present in...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Myxovirus resistance protein A in peripheral blood predicts supplemental oxygen need in COVID-19
Satoko Nakamura ... Toshimitsu Ito
Journal of Infection | VOL. 82
Satoko Nakamura, et. al.Satoko Nakamura ... Toshimitsu Ito
08 Dec 2020
Diagnosis of Viral Infections Using Myxovirus Resistance Protein A (MxA)
Ilka Engelmann ... Anny Dewilde
Pediatrics | VOL. 135
Ilka Engelmann, et. al.Ilka Engelmann ... Anny Dewilde
01 Apr 2015
Myxovirus resistance protein A for discriminating between viral and bacterial lower respiratory tract infections in children – The TREND study
Malin Ryd-Rinder ... Jesper Gantelius
Clinical Microbiology and Infection | VOL. 28
Malin Ryd-Rinder, et. al.Malin Ryd-Rinder ... Jesper Gantelius
18 May 2022
AB0082 PERSISTENT LOW COMPLEMENT LEVELS AND INTERFERON GENE UPREGULATION ARE PREDICTIVE FOR DISEASE PROGRESSION IN PATIENTS WITH INCOMPLETE SYSTEMIC LUPUS ERYTHEMATOSUS
H Bootsma ... B Doornbos- Van Der Meer
-
H Bootsma, et. al.H Bootsma ... B Doornbos- Van Der Meer
19 May 2021
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers